Literature DB >> 29388121

Techniques for Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.

Rebecca M Dodson1, Michael Kuncewitch1, Konstantinos I Votanopoulos1, Perry Shen1, Edward A Levine2.   

Abstract

Mesh:

Year:  2018        PMID: 29388121     DOI: 10.1245/s10434-018-6336-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  5 in total

1.  Surgical management for peritoneal carcinomatosis of appendiceal origin with a high-tumor burden.

Authors:  Toshiyuki Kitai; Kenya Yamanaka; Naoko Sugimoto; Osamu Inamoto
Journal:  Surg Today       Date:  2019-07-30       Impact factor: 2.549

2.  Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma.

Authors:  Yasmin M Ali; Joseph Sweeney; Perry Shen; Konstantinos I Votanopoulos; Richard McQuellon; Katie Duckworth; Kathleen C Perry; Greg Russell; Edward A Levine
Journal:  Ann Surg Oncol       Date:  2019-05-08       Impact factor: 5.344

Review 3.  Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Summary of Key Clinical Trials.

Authors:  Kevin M Turner; Mackenzie C Morris; Davendra Sohal; Jeffrey J Sussman; Gregory C Wilson; Syed A Ahmad; Sameer H Patel
Journal:  J Clin Med       Date:  2022-06-14       Impact factor: 4.964

Review 4.  Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations.

Authors:  Laura M Enomoto; Perry Shen; Edward A Levine; Konstantinos I Votanopoulos
Journal:  Cancer Manag Res       Date:  2019-05-07       Impact factor: 3.989

5.  Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study.

Authors:  Pengfei Yu; Zeyao Ye; Gaiguo Dai; Yanqiang Zhang; Ling Huang; Yian Du; Xiangdong Cheng
Journal:  BMC Cancer       Date:  2020-11-16       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.